Gilead delivers knockout punch with new hepatitis C drug data
This article was originally published in Scrip
Executive Summary
Gilead Sciences trumped its rivals again in the battle for better hepatitis C treatments, showing that a once-daily combination pill wiped out the virus in a short amount of time for most patients in a study.